Table 1 Participant demographics and baseline disease characteristics
Characteristics | Axi-cel + rituximab (n = 26) |
|---|---|
Median age, years (range) | 62.5 (38–82) |
 ≥65 years, n (%) | 12 (46) |
Male, n (%) | 14 (54) |
Race, n (%) | |
 White | 19 (73) |
 Asian | 3 (12) |
 Other | 4 (15) |
Ethnicity, n (%) | |
 Not Hispanic or Latino | 21 (81) |
 Hispanic or Latino | 4 (15) |
 Not reported | 1 (4) |
DLBCL type, n (%) | |
 DLBCL not otherwise specified | 16 (62) |
 Primary mediastinal LBCL | 1 (4) |
 DLBCL arising from FL | 6 (23) |
 High-grade BCL | 3 (12) |
Cell of origin, n (%) | |
 GCB | 15 (58) |
 ABC | 5 (19) |
 Other | 4 (15) |
 Not tested | 2 (8) |
ECOG performance status, n (%) | |
 0 | 12 (46) |
 1 | 14 (54) |
Disease stage, n (%) | |
 I | 2 (8) |
 II | 3 (12) |
 III | 5 (19) |
 IV | 16 (62) |
Disease stage extent, n (%) | |
 Presence of B symptoms | 3 (12) |
 Splenic involvement | 6 (23) |
 Extranodal disease | 16 (62) |
 Bulky diseasea | 2 (8) |
Refractory subgroup, n (%) | |
 Primary refractory | 5 (19) |
 Refractory to ≥2 lines of therapy | 19 (73) |
 Refractory after ASCT | 2 (8) |
aaIPI total score, n (%) | |
 0 | 4 (15) |
 1 | 13 (50) |
 2 | 9 (35) |
Median LDH, units per liter (range) | 246.0 (126.0–1,664.0) |
Elevated LDHb, n (%) | 10 (38) |
Median tumor burden (sum of products of diameters), mm2 (range) | 2,225.5 (187.0–14,884.0) |
Double/triple hit status, n (%) | |
 Double hit | 6 (23) |
 Negative | 16 (62) |
 Not tested | 4 (15) |
Alterations/overexpression, n (%) | |
 BCL2 | 22 (85) |
 BCL6 | 11 (42) |
 c-Myc | 9 (35) |
Number of prior therapies, n (%) | |
 1 | 5 (19) |
 2 | 19 (73) |
 ≥3 | 2 (8) |
Prior autologous transplant, n (%) | 2 (8) |
Prior radiotherapy, n (%) | 4 (15) |
